Cantor Fitzgerald Comments on Annexon FY2026 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Annexon in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($1.29) per share for the year. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

A number of other equities analysts have also issued reports on the company. HC Wainwright decreased their price objective on Annexon from $20.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Needham & Company LLC decreased their target price on shares of Annexon from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th.

Annexon Stock Up 0.3%

ANNX stock opened at $2.65 on Wednesday. The firm’s 50-day simple moving average is $1.87 and its 200 day simple moving average is $3.15. The stock has a market cap of $290.41 million, a PE ratio of -2.51 and a beta of 1.26. Annexon has a fifty-two week low of $1.29 and a fifty-two week high of $7.85.

Annexon (NASDAQ:ANNX) last issued its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07).

Institutional Investors Weigh In On Annexon

Several large investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its holdings in Annexon by 4.3% in the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company’s stock valued at $728,000 after purchasing an additional 5,854 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Annexon by 143.4% in the 4th quarter. New York State Common Retirement Fund now owns 34,479 shares of the company’s stock valued at $177,000 after purchasing an additional 20,311 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Annexon by 2.8% in the 4th quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company’s stock valued at $1,183,000 after purchasing an additional 6,226 shares in the last quarter. Mutual of America Capital Management LLC grew its holdings in shares of Annexon by 56.2% in the 4th quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock worth $5,282,000 after purchasing an additional 370,426 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Annexon by 1.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 743,795 shares of the company’s stock worth $3,816,000 after purchasing an additional 11,579 shares in the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.